Previous Close | 35.41 |
Open | 35.40 |
Bid | 36.50 x 900 |
Ask | 36.57 x 1200 |
Day's Range | 34.03 - 35.52 |
52 Week Range | 16.95 - 49.50 |
Volume | |
Avg. Volume | 1,479,416 |
Market Cap | 2.782B |
Beta (5Y Monthly) | 1.80 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.72 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 49.33 |
Subscribe to Yahoo Finance Plus to view Fair Value for BEAM
As you might know, Beam Therapeutics Inc. ( NASDAQ:BEAM ) just kicked off its latest annual results with some very...
One thing we could say about the analysts on Beam Therapeutics Inc. ( NASDAQ:BEAM ) - they aren't optimistic, having...
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference, emerging genetic therapy approaches corporate panel discussion on Wednesday, March 6, 2024 at 12:50 p.m. ETLeerink Partners Global Biopharma Conference, fireside chat on Monday, Marc